{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:20:01Z","timestamp":1791559201850,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.oret.2021.03.010","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T20:29:25Z","timestamp":1616790565000},"page":"15-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Recurrent Neovascular Age-Related Macular Degeneration after Discontinuation of Vascular Endothelial Growth Factor Inhibitors Managed in a Treat-and-Extend Regimen"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9407-0541","authenticated-orcid":false,"given":"Stamatios","family":"Aslanis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"Amr\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0399-3138","authenticated-orcid":false,"given":"David","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2021.03.010_bib1","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1001\/jama.291.15.1900","article-title":"Age-related macular degeneration is the leading cause of blindness","volume":"291","author":"Bressler","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.oret.2021.03.010_bib2","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","article-title":"Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study","volume":"122","author":"Gillies","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.03.010_bib3","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jamaophthalmol.2019.1971","article-title":"Analysis of anti\u2013vascular endothelial growth factor injection claims data in US Medicare Part B beneficiaries from 2012 to 2015","volume":"137","author":"Berkowitz","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2021.03.010_bib4","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1186\/s12913-019-4666-0","article-title":"Incremental economic burden associated with exudative age-related macular degeneration: a population-based study","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.oret.2021.03.010_bib6","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","article-title":"Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol","volume":"122","author":"Berg","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.03.010_bib7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.oret.2017.07.009","article-title":"Recurrence rate of choroidal neovascularization in neovascular age-related macular degeneration managed with a treat-extend-stop protocol","volume":"2","author":"Adrean","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2021.03.010_bib8","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.oret.2019.05.013","article-title":"Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months","volume":"3","author":"Nguyen","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2021.03.010_bib9","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.03.010_bib10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","article-title":"Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.oret.2021.03.010_bib11","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2021.03.010_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/eye.2016.208","article-title":"Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents","volume":"31","author":"Gemenetzi","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2021.03.010_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","article-title":"Incidence and growth of geographic atrophy during 5 years of Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"124","author":"Grunwald","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.03.010_bib14","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.03.010_bib15","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1097\/IAE.0000000000001451","article-title":"Recurrence of choroidal neovascularization lesion activity after aflibercept treatment for age-related macular degeneration","volume":"37","author":"Wakazono","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.oret.2021.03.010_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/IAE.0000000000001923","article-title":"Exit strategy in a treat-and-extend regimen for exudative age-related macular","volume":"39","author":"Arendt","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.oret.2021.03.010_bib17","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.ophtha.2016.07.012","article-title":"Treatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degeneration","volume":"123","author":"Essex","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.03.010_bib18","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1167\/iovs.10-6617","article-title":"Spectral-domain optical coherence tomography as an indicator of fluorescein angiography leakage from choroidal neovascularization","volume":"52","author":"Giani","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2021.03.010_bib19","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.ophtha.2009.11.039","article-title":"Agreement of time-domain and spectral-domain optical coherence tomography with fluorescein leakage from choroidal neovascularization","volume":"117","author":"Khurana","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.03.010_bib20","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/S0161-6420(99)90340-8","article-title":"Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration","volume":"106","author":"Sunness","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.03.010_bib21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ophtha.2018.07.013","article-title":"Intralesional macular atrophy in anti-vascular endothelial growth factor therapy for age-related macular degeneration in the IVAN Trial","volume":"126","author":"Bailey","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.03.010_bib22","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/aos.14239","article-title":"Twelve per cent of 6142 eyes treated for neovascular age-related macular degeneration (nAMD) presented with low visual outcome within 2 years. Analysis from the Swedish Macula Registry (SMR)","volume":"98","author":"Schroeder","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2021.03.010_bib23","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/bjophthalmol-2014-305186","article-title":"Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy","volume":"98","author":"Ritter","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2021.03.010_bib24","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ophtha.2014.11.017","article-title":"Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration","volume":"122","author":"Schmidt-Erfurth","year":"2015","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653021000993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653021000993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:30:07Z","timestamp":1762853407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653021000993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2468653021000993"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2021.03.010","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrent Neovascular Age-Related Macular Degeneration after Discontinuation of Vascular Endothelial Growth Factor Inhibitors Managed in a Treat-and-Extend Regimen","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2021.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}